FDA Expands Casgevy Gene Therapy Approval to Children as Young as 2 with Sickle Cell Disease

First CRISPR-based gene therapy approved for young children with sickle cell disease

The U.S. Food and Drug Administration (FDA) has approved an expanded indication for Casgevy (exagamglogene autotemcel), allowing its use in children as young as 2 years old with sickle cell disease (SCD) experiencing recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT).

The decision marks the first gene therapy approved for children ages 2 and older with sickle cell disease, significantly expanding access to one of the most advanced treatments currently available for these inherited blood disorders.

Casgevy was previously approved in 2023 for patients 12 years of age and older.

How Casgevy Works

Casgevy is a one-time, personalized gene therapy that uses the patient’s own blood-forming stem cells.

The treatment employs CRISPR/Cas9 gene-editing technology to modify the patient’s DNA outside the body. After the edited stem cells are infused back into the patient, they produce increased levels of fetal hemoglobin (HbF), which prevents red blood cells from developing the abnormal sickle shape responsible for painful vaso-occlusive crises.

For patients with transfusion-dependent beta thalassemia, increased fetal hemoglobin production can eliminate the need for ongoing blood transfusions.

Before receiving the therapy, patients undergo myeloablative conditioning, an intensive chemotherapy regimen that prepares the bone marrow to receive the modified stem cells.

Clinical Results

Sickle Cell Disease

Among pediatric patients aged 5 to under 12 years, 8 of 8 evaluable patients (100%) experienced no severe vaso-occlusive crises for at least 12 consecutive months within the first two years after treatment.

Beta Thalassemia

Among pediatric patients, 8 of 9 evaluable patients achieved transfusion independence for at least 12 consecutive months, and median duration of transfusion independence was 20.1 months.

FDA extended the indication to children 2 years and older based on these clinical data together with scientific evidence supporting use in younger patients.

Safety Profile

The most common adverse reactions included mucositis, febrile neutropenia, and decreased appetite.

The prescribing information also includes warnings regarding neutrophil engraftment failure, delayed platelet recovery, hypersensitivity reactions, and potential off-target CRISPR genome editing.

Expedited FDA Review

The supplemental application was approved just 53 days after filing through the FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program, making it the eighth product approved under the initiative.

Casgevy also received orphan drug designation, regenerative medicine advanced therapy (RMAT) designation, and fast track designation.

The therapy is manufactured by Vertex Pharmaceuticals.

Why It Matters

Sickle cell disease and transfusion-dependent beta thalassemia are lifelong genetic disorders that often begin causing irreversible organ damage during childhood.

By extending approval to children as young as two years old, FDA is making curative-intent gene therapy available much earlier in the disease process, when preventing long-term complications may have the greatest impact.

The approval also represents another milestone in the clinical application of CRISPR gene editing, moving genome editing beyond experimental medicine and into earlier intervention for inherited diseases.

Regulatory Insight

Gene Editing Is Entering a New Regulatory Era

Casgevy’s expanded approval reflects more than a pediatric indication. It demonstrates how FDA is becoming increasingly comfortable regulating gene-editing therapies as evidence accumulates.

When Casgevy was first approved, it marked the world’s first FDA-approved CRISPR-based therapy. This latest decision extends that confidence to much younger patients, recognizing that treating inherited diseases earlier may prevent irreversible organ damage before it occurs.

The approval also highlights FDA’s evolving use of scientific extrapolation. Rather than requiring large clinical trials in every pediatric age group, the agency combined strong clinical results in older children with established knowledge of the disease and product biology to support approval for patients as young as two years of age.

Finally, the review itself demonstrates FDA’s growing emphasis on accelerating therapies for serious conditions. Casgevy received approval just 53 days after filing through the Commissioner’s National Priority Voucher (CNPV) Pilot Program while also benefiting from Fast Track, RMAT, and Orphan Drug designations.

Regulatory Lesson

Modern biologics regulation is increasingly focused on delivering transformative therapies to patients sooner—not by lowering evidentiary standards, but by combining expedited review pathways, advanced science, and risk-based regulatory decision-making.

Intersurgical 22mm Smoothbore Breathing Tubes and Systems

FDA Issues Early Alert for Intersurgical Breathing Systems Over Potential Ventilation Failure. Manufacturing defect may cause breathing tube connectors to separate during use, potentially interrupting ventilation and exposing patients to serious injury or death.The...

FDA Early Alert: Teleflex/Arrow Guidewire

Affected guidewires and catheter products may release hydrophilic polymer particles into the bloodstream, potentially causing serious injury or death. No serious injuries or deaths have been reported.The U.S. Food and Drug Administration (FDA) has issued an Early...

Class 1 Recall for HemosIL AcuStar HIT Antibody Test

HemosIL AcuStar HIT-IgG(PF4-H). Source: fda.govPerformance problems could produce false-negative results, potentially delaying diagnosis of a dangerous reaction to heparin.The U.S. Food and Drug Administration (FDA) has identified a recall of certain lots of the...

Closing the Arterial Opening Without Surgery

Vivasure Medical's PerQseal Elite offers a minimally invasive approach to closing large arterial openings following cardiovascular procedures.Vivasure Medical's PerQseal Elite offers a minimally invasive approach to closing large arterial openings following...

FDA Approves Amplatzer Paraclose for Heart Valve Leaks

Abbott's Amplatzer Paraclose PVL Occluder offers a minimally invasive alternative for patients who develop a significant complication following heart valve replacement surgery.Heart valve replacement surgery can be lifesaving for patients with damaged or diseased...

October 2026 Premarket Approval (PMA) Authorizations

Three original device approvals and 218 supplements / noticesFDA's October activity highlights three newly approved medical devices and the extensive regulatory oversight required to maintain and modify products already on the market.The U.S. Food and Drug...

Pharma Innovation
Medical Device Innovation